DO-BO

Where Does AI Really Add Value in Market Access, Dr. Seye Abogunrin?

Everyone wants AI to click the button for them — the real question is whether you still need to click it at all. In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Seye Abogunrin, a health economist at Roche, Switzerland, to move AI in market access from experimentation to execution.

They explore where AI adds real value today — drafting dossier text, screening titles and abstracts, extracting data from full-text papers — and why out-of-the-box prompting isn’t enough. Seye makes the case that AI delivers strong first drafts, not submission-ready evidence, and that the human must stay “in the lead” for scientific rigor and credibility. They also unpack the real blockers at scale — change management, compliance, and data leakage — and why fully leveraging AI may mean overhauling our processes, not just speeding them up. The conversation also looks at how to identify the use cases that are genuinely worth scaling, rather than adopting AI for the sake of it. And as AI becomes more capable, the bigger opportunity may be to rethink how market access work gets done — not simply to make existing processes faster.

Related

In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Maurice Kléber to explore what building a winning team really takes — drawing on 18 years of leadership and a shared love of ice hockey. They discuss why trust and psychological safety are the foundation of any high-performing […]

By the time most health economists get pulled in, the recipe is already set. In this episode of MAP — the Market Access Podcast, Dr. Stefan Walzer sits down with two industry veterans — Dr. Björn Schwander, Founder of AHEAD GmbH and a specialist in early health economic modeling, and Julie Frappier, senior health economist […]

This is a repost of a popular episode of MAP – Market Access Podcast, from March 1st 2025. In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam Skali, unpacks the complexities of how GDPR regulations affect real-world evidence, cross-border studies, and market access in Europe. The discussion highlights data […]